Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseases we target
    • Diseases we target
    • GS010 (lenadogene nolparvovec)
    • GS030
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors
    • Company Overview
    • Financial press releases
    • Events & presentations
    • News and press coverage
    • Stock information
    • Governance
    • Documentation
  • Media

Our technologies

To bring the most advanced scientific thinking to finding a treatment for inherited neurodegenerative diseases, we combine gene therapy with platforms such as mitochondrial targeting sequence and optogenetics.
Direct access
  • Technologies we are applying
  • Gene Therapy
  • Mitochondrial Targeting Sequence (MTS)
  • Optogenetics
  • Home >
  • Our technologies
  • Technologies we are applying
  • Gene Therapy
  • Mitochondrial Targeting Sequence (MTS)
  • Optogenetics
© 2022 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page